NewsGlobeNewswire
Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome
· Published
Article summary
Anavex now has open INDs in all three core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…